Nantahala Capital Management LLC Purchases New Holdings in Inhibikase Therapeutics, Inc. (NYSE:IKT)

Nantahala Capital Management LLC bought a new stake in Inhibikase Therapeutics, Inc. (NYSE:IKT - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 2,190,000 shares of the company's stock, valued at approximately $7,118,000. Nantahala Capital Management LLC owned about 3.16% of Inhibikase Therapeutics at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in IKT. Stifel Financial Corp acquired a new stake in Inhibikase Therapeutics during the fourth quarter worth about $43,000. Alpine Global Management LLC purchased a new stake in shares of Inhibikase Therapeutics during the 4th quarter worth about $48,000. Northern Trust Corp purchased a new position in Inhibikase Therapeutics in the fourth quarter valued at approximately $208,000. Barclays PLC acquired a new position in Inhibikase Therapeutics during the fourth quarter valued at approximately $273,000. Finally, Blair William & Co. IL grew its stake in Inhibikase Therapeutics by 7.0% during the fourth quarter. Blair William & Co. IL now owns 134,953 shares of the company's stock worth $439,000 after buying an additional 8,833 shares during the period. 3.81% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a "neutral" rating on shares of Inhibikase Therapeutics in a report on Friday, March 28th.

Inhibikase Therapeutics Stock Performance

Shares of NYSE:IKT traded up $0.01 during mid-day trading on Friday, hitting $2.25. 116,487 shares of the company traded hands, compared to its average volume of 231,455. The firm has a market cap of $167.27 million, a P/E ratio of -0.84 and a beta of 1.02. Inhibikase Therapeutics, Inc. has a 52-week low of $1.12 and a 52-week high of $4.20. The firm's 50 day simple moving average is $2.13 and its 200 day simple moving average is $2.52.

Inhibikase Therapeutics Profile

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.